Dan O’Shannessy, Ph.D.
Senior Director, Translational Medicine and Diagnostics
Daniel J. O'Shannessy, Ph.D. has over 18 years experience in a combination of scientific, business development and strategic planning roles within the life sciences industry. In recent years Dr. O'Shannessy has held the positions of Chief Operating Officer of Targeted Diagnostics & Therapeutics, Inc. (TDT, West Chester, PA), Senior Director of Strategic Planning, Oncology Diagnostics at Gen-Probe, Inc. of San Diego, California, and Chief Scientific Officer at Fujirebio Diagnostics, Inc. (FDI, Malvern, PA).
While Chief Operating Officer at TDT, Dr. O’Shannessy was responsible for the day-to-day operations of the company including oversight of the company’s CLIA laboratory, approved for high complexity (RT-PCR) testing services for colon cancer. Further, he was closely involved in license negotiations surrounding the company’s proprietary technology and in ensuring adequate IP protection.
As Senior Director of Strategic Planning at Gen-probe, Dr. O’Shannessy was responsible for all aspects of the strategic implementation of prostate cancer diagnostic technologies and for leading Gen-Probe's efforts to expand its presence in oncology diagnostics.
As CSO of FDI, he was responsible for directing the strategic growth of the company with respect to new diagnostic products and technologies. He built and had direct responsibility for the departments of R&D, Clinical Affairs, Regulatory Affairs and Business Development, and was successful in in-licensing several novel oncology diagnostic markers. Importantly, he was successful in gaining U.S. FDA approval for a novel diagnostic for pancreatic cancer and initiating the approval process for the world’s first diagnostic for mesothelioma.
Dr. O'Shannessy has also held appointments as the Director of Business Development for Alchemia, an Australian biotech company, and spent 9 years at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) in Philadelphia, in both drug discovery/development and business development roles.
Dr. O'Shannessy received his B.Sc., Biochemistry and B.Sc., Honours Biochemistry degrees from the University of Queensland, Australia, and his Ph.D., Biochemistry from the University of Auckland, New Zealand in 1983. Dr. O'Shannessy was a Visiting Fellow at the National Institute for Neurological, Communicative Disorders and Stroke (NINCDS) of the NIH, under the guidance of Dr. Roscoe Brady. Subsequent to the NIH, Dr. O'Shannessy was a Docent in Biochemistry at the University of Lund, Sweden.